KRYS Quote, Financials, Valuation and Earnings

Alnylam Pharmaceuticals, Inc. has a net margin of 47.99% compared to Krystal Biotech, Inc.'s net margin of 16.99%. Krystal Biotech, Inc.'s return on equity of 19.22% beat Alnylam Pharmaceuticals, Inc.'s return on equity of 107.73%.

Krystal Biotech, Inc. has a consensus price target of $306.56, signalling upside risk potential of 17.1%. On the other hand Alnylam Pharmaceuticals, Inc. has an analysts' consensus of $457.00 which suggests that it could grow by 35.94%. Given that Alnylam Pharmaceuticals, Inc. has higher upside potential than Krystal Biotech, Inc., analysts believe Alnylam Pharmaceuticals, Inc. is more attractive than Krystal Biotech, Inc..

Krystal Biotech, Inc. has a beta of 0.493, which suggesting that the stock is 50.719% less volatile than S&P 500. In comparison Alnylam Pharmaceuticals, Inc. has a beta of 0.350, suggesting its less volatile than the S&P 500 by 65.025%.

Krystal Biotech, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alnylam Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Krystal Biotech, Inc. pays -- of its earnings as a dividend. Alnylam Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Krystal Biotech, Inc. quarterly revenues are $107.1M, which are smaller than Alnylam Pharmaceuticals, Inc. quarterly revenues of $1.1B. Krystal Biotech, Inc.'s net income of $51.4M is lower than Alnylam Pharmaceuticals, Inc.'s net income of $186.4M. Notably, Krystal Biotech, Inc.'s price-to-earnings ratio is 38.25x while Alnylam Pharmaceuticals, Inc.'s PE ratio is 148.95x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Krystal Biotech, Inc. is 20.13x versus 12.08x for Alnylam Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

DexCom, Inc. has a net margin of 47.99% compared to Krystal Biotech, Inc.'s net margin of 21.22%. Krystal Biotech, Inc.'s return on equity of 19.22% beat DexCom, Inc.'s return on equity of 33.68%.

Krystal Biotech, Inc. has a consensus price target of $306.56, signalling upside risk potential of 17.1%. On the other hand DexCom, Inc. has an analysts' consensus of $85.46 which suggests that it could grow by 16.94%. Given that Krystal Biotech, Inc. has higher upside potential than DexCom, Inc., analysts believe Krystal Biotech, Inc. is more attractive than DexCom, Inc..

Krystal Biotech, Inc. has a beta of 0.493, which suggesting that the stock is 50.719% less volatile than S&P 500. In comparison DexCom, Inc. has a beta of 1.491, suggesting its more volatile than the S&P 500 by 49.074%.

Krystal Biotech, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. DexCom, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Krystal Biotech, Inc. pays -- of its earnings as a dividend. DexCom, Inc. pays out -- of its earnings as a dividend.

Krystal Biotech, Inc. quarterly revenues are $107.1M, which are smaller than DexCom, Inc. quarterly revenues of $1.3B. Krystal Biotech, Inc.'s net income of $51.4M is lower than DexCom, Inc.'s net income of $267.3M. Notably, Krystal Biotech, Inc.'s price-to-earnings ratio is 38.25x while DexCom, Inc.'s PE ratio is 34.92x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Krystal Biotech, Inc. is 20.13x versus 6.36x for DexCom, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Amicus Therapeutics, Inc. has a net margin of 47.99% compared to Krystal Biotech, Inc.'s net margin of 0.91%. Krystal Biotech, Inc.'s return on equity of 19.22% beat Amicus Therapeutics, Inc.'s return on equity of -12.36%.

Krystal Biotech, Inc. has a consensus price target of $306.56, signalling upside risk potential of 17.1%. On the other hand Amicus Therapeutics, Inc. has an analysts' consensus of $14.50 which suggests that it could grow by 1.12%. Given that Krystal Biotech, Inc. has higher upside potential than Amicus Therapeutics, Inc., analysts believe Krystal Biotech, Inc. is more attractive than Amicus Therapeutics, Inc..

Krystal Biotech, Inc. has a beta of 0.493, which suggesting that the stock is 50.719% less volatile than S&P 500. In comparison Amicus Therapeutics, Inc. has a beta of 0.381, suggesting its less volatile than the S&P 500 by 61.857%.

Krystal Biotech, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amicus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Krystal Biotech, Inc. pays -- of its earnings as a dividend. Amicus Therapeutics, Inc. pays out -- of its earnings as a dividend.

Krystal Biotech, Inc. quarterly revenues are $107.1M, which are smaller than Amicus Therapeutics, Inc. quarterly revenues of $185.2M. Krystal Biotech, Inc.'s net income of $51.4M is higher than Amicus Therapeutics, Inc.'s net income of $1.7M. Notably, Krystal Biotech, Inc.'s price-to-earnings ratio is 38.25x while Amicus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Krystal Biotech, Inc. is 20.13x versus 6.99x for Amicus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals, Inc. has a net margin of 47.99% compared to Krystal Biotech, Inc.'s net margin of 21.74%. Krystal Biotech, Inc.'s return on equity of 19.22% beat Regeneron Pharmaceuticals, Inc.'s return on equity of 14.93%.

Krystal Biotech, Inc. has a consensus price target of $306.56, signalling upside risk potential of 17.1%. On the other hand Regeneron Pharmaceuticals, Inc. has an analysts' consensus of $869.96 which suggests that it could grow by 11.58%. Given that Krystal Biotech, Inc. has higher upside potential than Regeneron Pharmaceuticals, Inc., analysts believe Krystal Biotech, Inc. is more attractive than Regeneron Pharmaceuticals, Inc..

Krystal Biotech, Inc. has a beta of 0.493, which suggesting that the stock is 50.719% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals, Inc. has a beta of 0.398, suggesting its less volatile than the S&P 500 by 60.232%.

Krystal Biotech, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals, Inc. offers a yield of 0.46% to investors and pays a quarterly dividend of $0.94 per share. Krystal Biotech, Inc. pays -- of its earnings as a dividend. Regeneron Pharmaceuticals, Inc. pays out 8.49% of its earnings as a dividend. Regeneron Pharmaceuticals, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Krystal Biotech, Inc. quarterly revenues are $107.1M, which are smaller than Regeneron Pharmaceuticals, Inc. quarterly revenues of $3.9B. Krystal Biotech, Inc.'s net income of $51.4M is lower than Regeneron Pharmaceuticals, Inc.'s net income of $844.6M. Notably, Krystal Biotech, Inc.'s price-to-earnings ratio is 38.25x while Regeneron Pharmaceuticals, Inc.'s PE ratio is 18.76x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Krystal Biotech, Inc. is 20.13x versus 5.90x for Regeneron Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.